Mirtazapine use may increase the risk of hypothyroxinaemia in patients affected by major depressive disorder
Autor: | Mingcan Li, Ruiling Zhang, Desheng Zhai, Yuan Yuan, Ying Zhao, Ravi Retnakaran, Shi Wu Wen, Na Wang, Wei Hao |
---|---|
Rok vydání: | 2021 |
Předmět: |
Pharmacology
Depressive Disorder Major Pediatrics medicine.medical_specialty business.industry Incidence Incidence (epidemiology) Thyroid Confounding Mirtazapine Retrospective cohort study medicine.disease medicine.anatomical_structure Relative risk medicine Humans Major depressive disorder Pharmacology (medical) business Depression (differential diagnoses) Retrospective Studies medicine.drug |
Zdroj: | British Journal of Clinical Pharmacology. 88:214-225 |
ISSN: | 1365-2125 0306-5251 |
DOI: | 10.1111/bcp.14949 |
Popis: | Aims Hypothyroxinaemia could be easily neglected if attention is paid only to patients with elevated thyroid-stimulating hormone. We aimed to assess the association between mirtazapine use and hypothyroxinaemia in patients affected by major depressive disorder. Methods We conducted a retrospective cohort study in the Second Affiliated Hospital of Xinxiang Medical University between January 2016 and December 2018. Patients affected by major depression disorder and admitted to the hospital for treatment during the study period and who had thyroid tests at admission and after treatment were included. Mirtazapine use during hospitalization was the exposure measure and newly developed hypothyroxinaemia was as the primary outcome and structure parameters of thyroid homeostasis were the secondary outcomes of this study. Log-binomial model was used to estimate the association between mirtazapine use and hypothyroxinaemia, after adjusting for potential confounding factors. Results A total of 220 eligible patients were included in the final analysis. The incidence of hypothyroxinaemia in patients who used mirtazapine was higher (37.5%) than those patients who did not use (19.7%). The relative risk of developing hypothyroxinaemia was 1.70 (95% confidence interval: 1.21-2.43) for mirtazapine use, after adjusting for confounding factors. The degree of reduction in thyroid feedback quantile-based index in mirtazapine group was significantly greater than that in nonmirtazapine group. Conclusion Mirtazapine use was associated with the increased risk of developing hypothyroxinaemia. The underlying mechanism may be involved the changed central set point of thyroid homeostasis, in which pituitary was in a possibly impaired sensitivity to the lower level of thyroid hormones. |
Databáze: | OpenAIRE |
Externí odkaz: |